The Maternal Screen (Quadruple Marker) test is a second-trimester prenatal screening performed between 14 to 22.6 weeks of pregnancy. It measures four key biochemical markers to help assess the risk of chromosomal abnormalities and certain fetal conditions. This test provides important insights for expectant mothers and supports timely clinical decisions with early risk evaluation.
Price:
Rs. 3,500.00
Sample Type: Serum
Fasting Not Required
Frequently Asked Questions (FAQ's):
What does the Maternal Screen (Quadruple Marker) test include?
It measures AFP, hCG, uE3, and Inhibin-A to evaluate fetal and chromosomal risk factors.
Who should take this test?
Pregnant women in the 14 to 22.6-week window who wish to assess fetal health and genetic risk.
How is the sample collected for this test?
A simple maternal blood sample is used for the screening.
Does this test diagnose fetal abnormalities?
No, it is a screening test that assesses risk but does not confirm a diagnosis.
Why is the 14 to 22.6-week period important?
These markers provide the most reliable predictive value during this specific gestational window.
How long does it take to receive results?
Reports are typically available within the standard prenatal screening timeframe.
Can this test help guide further prenatal decisions?
Yes, results can help determine whether additional diagnostic tests may be needed.
Is the test safe for the mother and baby?
Yes, it is completely safe as it only requires a routine blood sample.